Anti-S38A6/ SLC38A6/ NAT-1 monoclonal antibody

Anti-S38A6/ SLC38A6/ NAT-1 antibody for FACS & in-vivo assay

Target products collectionGo to SLC38A6/SLC38A6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1611-Ab-1/ GM-Tg-hg-MP1611-Ab-2Anti-Human SLC38A6 monoclonal antibodyHuman
GM-Tg-rg-MP1611-Ab-1/ GM-Tg-rg-MP1611-Ab-2Anti-Rat SLC38A6 monoclonal antibodyRat
GM-Tg-mg-MP1611-Ab-1/ GM-Tg-mg-MP1611-Ab-2Anti-Mouse SLC38A6 monoclonal antibodyMouse
GM-Tg-cynog-MP1611-Ab-1/ GM-Tg-cynog-MP1611-Ab-2Anti-Cynomolgus/ Rhesus macaque SLC38A6 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1611-Ab-1/ GM-Tg-felg-MP1611-Ab-2Anti-Feline SLC38A6 monoclonal antibodyFeline
GM-Tg-cang-MP1611-Ab-1/ GM-Tg-cang-MP1611-Ab-2Anti-Canine SLC38A6 monoclonal antibodyCanine
GM-Tg-bovg-MP1611-Ab-1/ GM-Tg-bovg-MP1611-Ab-2Anti-Bovine SLC38A6 monoclonal antibodyBovine
GM-Tg-equg-MP1611-Ab-1/ GM-Tg-equg-MP1611-Ab-2Anti-Equine SLC38A6 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1611-Ab-1/ GM-Tg-hg-MP1611-Ab-2; GM-Tg-rg-MP1611-Ab-1/ GM-Tg-rg-MP1611-Ab-2;
GM-Tg-mg-MP1611-Ab-1/ GM-Tg-mg-MP1611-Ab-2; GM-Tg-cynog-MP1611-Ab-1/ GM-Tg-cynog-MP1611-Ab-2;
GM-Tg-felg-MP1611-Ab-1/ GM-Tg-felg-MP1611-Ab-2; GM-Tg-cang-MP1611-Ab-1/ GM-Tg-cang-MP1611-Ab-2;
GM-Tg-bovg-MP1611-Ab-1/ GM-Tg-bovg-MP1611-Ab-2; GM-Tg-equg-MP1611-Ab-1/ GM-Tg-equg-MP1611-Ab-2
Products NameAnti-SLC38A6 monoclonal antibody
Formatmab
Target NameSLC38A6
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SLC38A6 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species S38A6/ SLC38A6/ NAT-1 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1611
    Target NameSLC38A6
    Gene ID145389,625098,299139,704017,612894,101082161,520243,100060809
    Gene Symbol and SynonymsEG625098,NAT-1,SLC38A6,SNAT6
    Uniprot AccessionQ8IZM9,Q6WWW3
    Uniprot Entry NameS38A6_HUMAN,S38A6_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000139974
    Target ClassificationN/A

    The target: SLC38A6, gene name: SLC38A6, also named as NAT-1, SNAT6. Predicted to enable L-glutamine transmembrane transporter activity. Predicted to be involved in amino acid transmembrane transport and glutamine transport. Predicted to be located in plasma membrane. Predicted to be integral component of plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.